Ozempic Class Action Lawsuit Alleges Failure to Warn About Gallbladder Disease

A class action lawsuit has been filed against Novo Nordisk, the manufacturer of Ozempic, alleging that the company failed to adequately warn patients about the risk of gallbladder disease and gallstones.

Ozempic is a prescription medication used to treat Type 2 diabetes and obesity. It is a once-weekly injection that works by mimicking the effects of the hormone glucagon-like peptide-1 (GLP-1).

The plaintiffs in the class action lawsuit allege that Novo Nordisk knew or should have known about the risk of gallbladder disease associated with Ozempic, but chose not to adequately warn patients. They also allege that Novo Nordisk has marketed Ozempic as a safe and effective weight loss medication, even though it is known to have the potential to cause serious side effects.

In Summary:

  • What is Ozempic? Ozempic is a prescription medication used to treat Type 2 diabetes and obesity. It is a once-weekly injection that works by mimicking the effects of the hormone glucagon-like peptide-1 (GLP-1).
  • What are the allegations against Ozempic? The plaintiffs in the class action lawsuit allege that Ozempic's manufacturer, Novo Nordisk, failed to adequately warn patients about the risk of gallbladder disease and gallstones. They also allege that Novo Nordisk knew or should have known about these risks, but chose to market Ozempic without adequate warnings.
  • What is the status of the lawsuit? The lawsuit is still ongoing. In March 2022, Novo Nordisk agreed to add a new warning to Ozempic's label about the risk of gallbladder disease. However, the plaintiffs are seeking additional compensation for the injuries they have suffered.
  • What are the potential outcomes of the lawsuit? It is difficult to say what the potential outcomes of the lawsuit are. However, if the plaintiffs are successful, they could be awarded damages for their injuries. They could also force Novo Nordisk to change the way it markets Ozempic.

In addition to the class action lawsuit, there have been other legal actions against Novo Nordisk related to Ozempic. In 2021, the FDA issued a warning about the risk of pancreatitis associated with Ozempic. Novo Nordisk also recalled some batches of Ozempic in 2022 due to concerns about contamination.

It is important to note that not everyone who takes Ozempic will experience gallbladder disease or gallstones. However, the risk of these side effects is higher for some people, such as those with a history of gallbladder disease. If you are taking Ozempic and are concerned about the risk of gallbladder disease, talk to your doctor.